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The CRISPR–Cas9 RNA-guided endonuclease system allows precise and efﬁcient modiﬁca-
tion of complex genomes and is continuously developed to enhance speciﬁcity, alter targeting
and add new functional moieties. However, one area yet to be explored is the base chemistry
of the associated RNA molecules. Here we show the design and optimisation of hybrid
DNA–RNA CRISPR and tracr molecules based on structure-guided approaches. Through
careful mapping of the ribose requirements of Cas9, we develop hybrid versions possessing
minimal RNA residues, which are sufﬁcient to direct speciﬁc nuclease activity in vitro and
in vivo with reduced off-target activity. We identify critical regions within these
molecules that require ribose nucleotides and show a direct correlation between binding
afﬁnity/stability and cellular activity. This is the ﬁrst demonstration of a non-RNA-guided
Cas9 endonuclease and ﬁrst step towards eliminating the ribose dependency of Cas9 to
develop a XNA-programmable endonuclease.
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Genome engineering of mammalian cells has been rapidlyadvancing in recent years due to the adoption of theCRISPR–Cas9 RNA-guided DNA endonuclease system.
Cas9 forms part of the bacterial and archaeal antiviral defence
mechanisms, which degrade genomes of invading pathogens1.
The most well-characterised version, the type II Cas9 protein
derived from Streptococcus pyogenes (for simplicity, hereafter
referred to as Cas9), relies on two associated RNA molecules to
achieve activity and speciﬁcity: (1) a 42-nucleotide (nt) RNA
molecule referred to as ‘clustered regularly interspaced short
palindromic repeat’ RNA (also CRISPR RNA or crRNA) and (2)
an 88-nt RNA molecule with constant sequence, known as trans-
activating crRNA (tracrRNA). The crRNA has a 20-nt ‘spacer’ or
‘guide’ sequence at the 5′-end, which is variable and homologous
to the intended DNA target sequence, and a ‘repeat’ sequence at
the 3′-end that duplexes with the tracrRNA. These RNA mole-
cules bind and span both the recognition and nuclease lobes
of the 160 kDa Cas9 protein, the latter of which contains the
HNH and RuvC nuclease domains2. Cas9 nuclease activity is a
multistep process involving large domain movements and
reorganisation3–6. Cas9 scans the genome searching for a 3 base-
pair (bp) NGG sequence via the protospacer adjacent motif
(PAM) recognition domain. Binding is transient unless both the
crRNA and tracrRNA are complexed, at which point the DNA
target is sequentially unwound and tested for complementarity
with the crRNA. If near full complementarity is achieved, the
HNH domain and recognition lobe undergo a conformational
change to bring the nuclease sites into correct proximity for DNA
cleavage (Supplementary Fig. 1 depicts the ﬁnal complex). Fol-
lowing cleavage, Cas9 remains bound to the DNA, possibly
releasing the PAM distal strand7. As Cas9 remains target-bound
after cleavage, it has been classiﬁed as a single-turnover enzyme8.
There has been interest in understanding the requirements and
sequence speciﬁcity of the crRNA and tracrRNA molecules to
help delineate the mechanism of Cas9 activity and allow
improved exploitation and manipulation of this system. Both
RNA molecules can be fused to create a fully functional single
guide RNA (sgRNA)9,10, and further sequence alterations and
deletion studies have improved both transcription and stability as
well as added new functional moieties9–11. Alterations to the
nucleotides within these RNA molecules, such as 2′-O-methyl
additions to the 2′-hydroxyl, have been found to reduce degra-
dation and enhance nuclease activity in primary and
immortalised cell lines12. These studies sought to further improve
the sgRNA platform, yet there have been no reports to date that
have addressed alternative nucleotide chemistry. The only che-
mical differences between RNA and DNA are a single hydroxyl
group at the 2′ location on the sugar molecule and an extra
methyl group on the thymine base, which substitutes for uracil.
The hydroxyl group leads to altered properties, with RNA
showing an increased preference for C3′-endo over C2′-endo
sugar pucker, resulting in the more symmetric base-stacked A-
form helix rather than the asymmetric B-form structure preferred
by DNA13,14. In addition to the structure, differing backbone
chemistries also alter the physical properties of nucleotide
duplexes13,14.
RNA is expensive to synthesise and the 2′-hydroxyl group in
the ribose ring increases rates of hydrolysis and degradation,
limiting its application and use. Improving these properties would
not only yield cost beneﬁts in the generation of CRISPR reagents
and libraries, but may represent a crucial step in advancing the
technology and leveraging its therapeutic potential. Further, the
high stability of RNA:DNA duplexes led to the excess energy
model for designing improved Cas9 systems: reducing the target-
binding energy does not perturb on-target activity but
signiﬁcantly reduces off-target activity15–17. We therefore postu-
lated that by manipulating the nucleotide backbone and ﬁne
tuning the duplex stability through modiﬁed nucleotide chem-
istry, it may be possible to signiﬁcantly modulate many char-
acteristics of the system, such as binding afﬁnity, speciﬁcity,
stability, in vitro and cellular activity, which would be crucial for
development of efﬁcacious CRISPR-based therapeutic entities.
To this aim, we here describe the ﬁrst, to our knowledge,
example of hybrid DNA–RNA CRISPR and tracr molecules that
direct speciﬁc Cas9 nuclease activity in vitro and in vivo and
possess unique biophysical properties, which could be exploited
in future applications.
Results
A DNA CRISPR molecule cannot direct Cas9 nuclease activity.
To understand the molecular composition of the co-associated
RNA molecules needed by Cas9, the requirement for RNA rather
than DNA nucleotides within the CRISPR molecule was inves-
tigated. We generated a speciﬁc crRNA and an equivalently
sequenced DNA molecule, a crDNA (CRISPR molecules will be
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Fig. 1 Cas9:tracrRNA complexed with RNA or hybrid crXNAs are nuclease competent. a Design of the crRNA, crDNA and crHyb sequence for GFP target
site 1 (GFP cr1). DNA shown in uppercase black, RNA shown in lowercase red. b Cas9, tracrRNA and crXNA molecules were incubated with linear double-
stranded DNA harbouring the GFP target sequence. Reaction products were analysed by agarose gel electrophoresis. The expected undigested and
digested fragments are exempliﬁed on the right. c Semiquantitative analysis of the cleavage of the linear DNA fragment by crDNA (blue)-, crHyb (black)-
and crRNA (red)-guided Cas9:tracrRNA complexes with three independent guide sequences. Bars show mean + SD, n= 3–7
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collectively referred to as crXNA hereafter; Fig. 1a). These crXNA
were designed to direct Cas9 to asymmetrically cleave a 790 bp
double-stranded DNA (dsDNA) molecule, encoding enhanced
green ﬂuorescent protein (eGFP), allowing assessment of nuclease
activity by DNA fragmentation. The assay was performed with
excess crXNA and tracrRNA to ensure full saturation of Cas9
protein, and used a limiting DNA target concentration to allow
for sensitive detection of cleavage activity. Cas9 protein alone was
unable to cleave the target molecule and required both crRNA
and tracrRNA for full activity, with speciﬁcity of cleavage shown
by generation of fragments of the expected size; 533 and 258 bp
(Fig. 1b). However, when a Cas9:tracrRNA:crDNA complex was
used, no cleavage product was detected, indicating that ribose
sugar moieties are essential for in vitro nuclease activity.
A hybrid DNA–RNA crXNA can direct Cas9 cleavage. The
absence of nuclease activity when using a crDNA molecule could
be due to loss of essential interactions with Cas9. Crystal struc-
tures of the Cas9:tracrRNA:crRNA complex with target DNA18
reported 32 hydrogen bonds between Cas9 and crRNA (Supple-
mentary Fig. 2); seven interactions rely on the ribose speciﬁc 2′
hydroxyl group (residues 1, 15, 16, 19, 22, 23 and 24 of crRNA),
of which four are located in the guide sequence, where the
nucleotides bind the target DNA, and three in the cr repeat
region, which duplex the tracrRNA (Supplementary Figs. 2 and
3). To test whether these interactions were required for activity, a
hybrid DNA–RNA crXNA molecule was generated, where 35
residues were coded as DNA and the 7 which make 2′ hydroxyl
bonds with Cas9 protein coded as RNA (hereafter referred to as
crHyb; Fig. 1a). The Cas9:tracrRNA:crHyb complex was nuclease
competent in the DNA fragmentation assay (Fig. 1b). A crHyb
molecule possessing only 7 RNA residues is therefore sufﬁcient to
direct speciﬁc Cas9 nuclease activity in vitro.
The replacement of uracil with thymine introduces extra
methyl groups into the crXNA molecule. This methyl group
should not impact base stacking with target DNA or tracrRNA.
The position of these groups within the crXNA was manually
modelled within the Cas9 crystal structure2 and we determined
that no methyl group would come within 5 Å of protein. This
suggests the presence of thymine bases would have no impact on
the activity of the complex. To validate these predictions, we
developed a quantitative PCR (qPCR) assay to report on template
depletion by Cas9 cleavage using guide sequences and a 1 kb
template sequence derived from the human AAVS1 locus. We
generated a crHyb.deoxy molecule, where all thymidine nucleo-
sides were replaced with deoxyuridine, to remove any additional
methyl groups compared to an equivalent crRNA molecule.
Assessing the ability of Cas9 complexes to cleave target DNA, we
found template depletion over time was unchanged when Cas9:
tracrRNA was complexed with crHyb or crHyb.deoxy, irrespec-
tive of Cas9 protein concentration (Supplementary Fig. 4). Thus,
thymine within the crXNA does not appear to impact Cas9
cleavage activity.
Cas9:tracrRNA binds stably to ribose-free crXNA. To under-
stand whether loss of activity was due to an inability of crDNA to
complex with Cas9 protein, surface plasma resonance (SPR) was
employed to measure binding kinetics of crXNA molecules to
Cas9:tracrRNA complexes. Catalytically inactive Cas9 (dCas9;
D10A and H840A) was immobilised to the SPR chip surface and
associated with tracrRNA; dCas9 showed nanomolar afﬁnity for
tracrRNA with slow dissociation kinetics (t1/2 ~ 0.5 h; Supple-
mentary Fig. 5a). Following assembly of this complex, binding
kinetics of crXNA molecules were measured; crRNA, crHyb and
crDNA showed comparable, high-afﬁnity binding to the dCas9:
tracrRNA complex in the subnanomolar range (Supplementary
Fig. 5b, c) in line with previous measurements for sgRNA-binding
afﬁnities19. Furthermore, the speciﬁcity of crHyb binding to Cas9:
tracrRNA was demonstrated by alteration of the cr repeat
sequence to abrogate duplexing with tracrRNA, which rendered
this crHyb (crHyb.duplex.mut) incapable of interaction (Sup-
plementary Fig. 5d). Therefore, Cas9:tracrRNA complexes couple
to crRNA, crDNA or crHybs with similar biophysical properties.
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Fig. 2 Cas9:tracrRNA can function with a crXNA composed of 88% DNA and crHyb show enhanced speciﬁcity. a RNA nucleosides within the crHyb
for GFP target 1 were sequentially converted to DNA and activity assessed by DNA fragmentation assay. Nucleotides coloured as in Fig. 1a. b A single base
C>A mismatch was introduced into crRNA and crHyb molecules and activity assessed. All bars show mean + SD, n= 3–13. c Kinetics of template
degradation driven by Cas9:tracrRNA complexed with crHyb (black) or crRNA (red), either with perfect complementary (left) or with a single base-pair
mismatch (right). Graphs show normalised template abundance (%) over time, with Cas9 protein at 5 nM (solid line), 2.5 nM (long dash line), 1.25 nM
(dot dash line) or 0.625 nM (dotted line). Error bars show SD of 3–4 independent measurements
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The ﬁnding that crDNA can bind to dCas9:tracrRNA
complexes with broadly similar afﬁnities to crRNA suggested
that the correct holocomplex can form, but that it is not
competent for either nuclease activity or target DNA recognition.
Interestingly, we were unable to detect binding of a dsDNA target
sequence when dCas9:tracrRNA:crXNA was immobilised on the
SPR chip, possibly due to conformational restrictions imposed by
immobilisation and covalent crosslinking.
crHybs direct sequence-speciﬁc Cas9 nuclease activity. Cas9
displays exquisite sequence-speciﬁc nuclease activity when
directed by a crRNA. To determine whether such speciﬁcity was
perturbed by crXNAs, three different regions of the same 790 bp
DNA molecule were targeted. It was found that both crRNAs and
crHybs showed robust in vitro nuclease activity at all target sites
(Fig. 1c). Moreover, the cleavage products generated by crRNA
and crHybs were identical, suggesting crHybs maintain the
sequence speciﬁcity of Cas9 targeting (Supplementary Figs. 6 and
7). As expected, all three crDNA molecules generated no cleavage
products.
Identiﬁcation of critical Cas9:crXNA contact points. To
determine whether all seven RNA nucleosides were required for
Cas9 activity, each nucleoside in turn was sequentially converted
to DNA and assessed for in vitro cleavage activity (Fig. 2a).
crHybs containing either residues 1, 15, 19 or 22 as DNA
nucleosides showed almost complete target DNA cleavage. Con-
version of residue 23 to DNA led to a reduction of activity by
50%, whereas conversion of residues 16 or 24 to DNA led to an
almost complete ablation of activity (Fig. 2a, top).
This analysis was extended by generating new crHybs with
combinations of two or three of the ﬁve DNA nucleosides shown
to have no adverse effect on activity. Synergies between which
nucleosides could tolerate coding as DNA were detected; coding
residues 1 and 22 or 19 and 22 as DNA had little effect on
activity, whereas combining residues 1 and 19 seriously com-
prised activity with cleavage reduced below 20% (Fig. 2a, bottom).
Combinations coding three residues as DNA were tested, but
these were found to result in either moderate or severe reduction
in activity. In summary, we have identiﬁed three key residues
within the crHyb molecule (residues 16, 23 and 24), which cannot
be coded as DNA. We have further described a fully active hybrid
design that contains only ﬁve RNA residues (residues 1, 15, 16, 23
and 24).
crHybs show reduced off-target activity. It has been demon-
strated that reducing the helicase activity in the Cas9–target
interaction increases the energy barrier needed to overcome
mismatches between the sgRNA and target DNA, leading to
increased speciﬁcity of the enzyme16,20,21. We questioned whe-
ther replacement of crRNA with the predominantly DNA coded
crHyb would lead to similar increased speciﬁcity due to the
reduced binding energy of a DNA–DNA duplex destabilising the
complex13. We generated a crRNA and crHyb, which contained a
C>A mutation at residue 5 (located in the non-seed region and
which showed no sensitivities for encoding as RNA or DNA) and
tested for activity on the unmodiﬁed DNA template. Whilst fully
matched crRNA showed almost complete cleavage of the target
DNA (Fig. 2a), the C>A mismatched crRNA showed a 30%
reduction in activity (Fig. 2b). However, while the fully matched
crHyb showed almost total cleavage of target DNA, when a single
C>A mismatch was introduced the nuclease activity was almost
completely ablated, with <4% activity detected (Fig. 2b). This
suggests crHybs possess similar on-target activity but reduced off-
target activity compared to crRNAs.
To determine whether the increased speciﬁcity was due to
lower overall activity of crHybs, we performed time-course
cleavage assays at multiple protein concentrations (Fig. 2c). For
these experiments we used the qPCR template depletion assay
described previously. We found clear dose-dependent and time-
dependent cleavage activity with Cas9:tracrRNA:crRNA and
Cas9:tracrRNA:crHyb complexes, with the latter showing overall
slower template depletion kinetics. We found that a single base-
pair mismatch in the crRNA resulted in only a slight perturbation
of cleavage activity with a two- to fourfold reduction in the rate
constant. However, the mismatched crHyb showed no detectable
activity at any time point or concentration, demonstrating a
much greater perturbation in catalytic activity.
Cas9 target engagement is severely compromised with crHybs.
To determine if coding the crXNA molecule predominately with
DNA caused reduced binding afﬁnity for target DNA, the kinetics
of the complex interaction were measured. BioLayer Inter-
ferometry (BLI) and SwitchSENSE assays were developed to
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monitor engagement of precomplexed dCas9:tracrRNA:crXNA
with immobilised target DNA. For these assays, short target
sequences derived from the human AAVS1 locus were used with
crXNAs containing the corresponding 20-nt guide sequence
(Fig. 3a). Both assays were able to validate binding of the dCas9:
tracrRNA:crRNA complex to target DNA with high afﬁnity and
negligible dissociation (Fig. 3b, c, Supplementary Fig. 10 and
Supplementary Table 2). However, an equivalent dCas9:
tracrRNA:crDNA complex showed no interaction with target
DNA (Fig. 3b, c), which corroborates the previously described
absence of cleavage activity when using crDNAs.
Previous reports have shown that ionic blockade of Cas9
protein, by the negatively charged molecule heparin, can affect
binding afﬁnities8. In our BLI assay we similarly found
polyanionic heparin reduced binding afﬁnities and rates of
association (Supplementary Fig. 11a). However, when heparin
was absent, there was an increase in non-speciﬁc interaction
between Cas9 (with or without associated RNA molecules) and
speciﬁc or non-speciﬁc target DNA (Supplementary Fig. 11b).
Addition of heparin completely abolishes binding to non-target
sequences as well as non-speciﬁc interaction of apoCas9 with
DNA.
Intriguingly, while both BLI and SwitchSENSE demonstrated
efﬁcient target recognition for Cas9:tracrRNA:crRNA complexes
and no recognition for crDNA equivalents, the binding data for
crHyb varied between the two methods. Using SwitchSENSE
(Fig. 3c), we determined that crHybs had intermediate afﬁnities,
with on-rates slower than the crRNA. Whereas in the BLI assay
(Fig. 3b), crHybs were signiﬁcantly less able to promote dsDNA
recognition (Fig. 3b, c and Supplementary Table 1).
To determine whether the reduced target-binding afﬁnity was
caused by a reduction of RNA in the guide or the cr repeat
sequence, we generated two additional crXNA molecules; crR.
Hyb and crD.Hyb (Fig. 3a). crR.Hyb coded only solvent accessible
residues in the cr repeat region as DNA. This assumed that there
would be no conformational restraints imposed by the protein on
this region and it could therefore tolerate the altered backbone
properties. crD.Hyb consists of a predominantly DNA guide
region and fully RNA cr repeat region. Interestingly, we found
that target-binding afﬁnity was modulated by residues in the
guide region. The BLI assay showed that crD.Hyb displayed weak
target binding very similar to crHyb. Conversely, crR.Hyb showed
an almost complete restoration of binding afﬁnity (Fig. 3b). Using
the orthogonal SwitchSENSE assay, despite crHyb performing
better than in the BLI assay, crD.Hyb showed binding kinetics
more similar, albeit still reduced, to crRNA. Thus, the ribose
residues within the guide area, rather than the solvent exposed
repeat region, appear most critical for target binding.
Stable target engagement is compromised with crHyb com-
plexes. Having found that crXNA-binding afﬁnities are reduced
with increasing DNA content, we then sought to determine
whether formation of the active complex is compromised.
We used a previously developed single-molecule Förster
resonance energy transfer (FRET) assay on our home-built
total internal reﬂection ﬂuorescence microscope to monitor
dCas9 binding, conformational changes and dynamics5,6,22.
Using biotin–streptavidin interactions, Cy3-labelled DNA
containing the AAVS1 target site was surface-immobilised on
a microscope slide (Fig. 4a and Supplementary Table 3; 5′
Bio-AAVS1-Cy3). We injected dCas9:tracrRNA:crXNA com-
plexes with Cy5-label at the 5′-end of the crXNA (Fig. 4a and
Supplementary Table 3). In this assay, binding of the dCas9
complex to the DNA yields a FRET signal between the donor
(Cy3) and acceptor (Cy5), the magnitude of which is dependent
on its conformational state (Fig. 4b and Supplementary Fig. 12).
With crRNA guide in the dCas9 complex, the majority of
single-molecule trajectories (66%, n= 60/91) reach a stable high-
FRET state (~ 0.95) which, in traces where the initial binding
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Fig. 4 Conformational dynamics of target-bound dCas9:trRNA:crXNA complexes. a Single-molecule FRET experimental design. Surface-immobilised
Cy3-labelled (green) DNA containing the AAVS1 target site (orange) and PAM site (white) binds Cy5-labelled (red) dCas9 complex (blue) to yield a FRET
signal. b Representative single-molecule FRET trajectories show dCas9–crRNA complex binding in heteroduplex conformation as an increase to high
FRET (top) through a transient intermediate (arrow). Irreversible conformational change into a dynamic intermediate FRET state (bottom). Corresponding
time-binned FRET histograms (right), and Gaussian ﬁts (black curves). Trajectories are 5 point averaged. c Time-binned FRET histograms for each guide:
crRNA (red, n= 91); crHyb (grey, n= 57); crD.Hyb (magenta, n= 197), and crR.Hyb (green, n= 172)
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event is observed, transition through a transient intermediate
FRET conformation (~ 0.5, arrow) with an average dwell time of
310± 40 ms (n= 30, Fig. 4b, top left). Based on previous studies,
we assigned these trajectories to initial binding in an open
conformation (~ 0.5 FRET, arrow) followed by zipping into a full
heteroduplex conformation (~ 0.95 FRET)5,6. A single-molecule
time-binned FRET histogram shows that these molecules
predominantly occupy the high-FRET conformation, as expected
(Fig. 4b, top right). Interestingly, a second population of
trajectories (34%, n= 31/91) reach the high-FRET conformation
but then transition irreversibly into a dynamic ensemble of states
characterised by rapid FRET ﬂuctuations from ~ 0.4 to ~ 0.9
FRET (Fig. 4b, bottom left). The corresponding time-binned
single-molecule histogram shows a narrow peak centred on ~ 1.0
and a broad peak at ~ 0.70 (Fig. 4b, bottom right). This
population may correspond to molecules that either unzip from
the fully duplexed conformation and repeatedly attempt to return
to it, or a protein conformational change that affects the local
environment of the FRET pair. This population of molecules may
not have been observed in previous studies, due to our work being
at near-physiological [Mg2+] (1 mM) rather than 10 mM in
previous studies5,6. A time-binned FRET histogram of 91
trajectories with crRNA shows that in the presence of a fully
RNA guide the complex predominantly exists in the fully
heteroduplex conformation (Fig. 4c, red), consistent with the
tight binding previously observed.
Increasing the DNA load in the dCas9 complex with a crHyb
guide resulted in eightfold fewer overall binding events, consistent
with the lower binding afﬁnity observed by BLI and SwitchSENSE
(Fig. 3b). Of the few binding events detected (n= 57), we
observed a fourfold decrease of stable high-FRET trajectories
(17.5%) in favour of traces demonstrating the dynamic broad
mid-FRET state (70%) and a minor (12%) previously unobserved
low-FRET (~ 0.2) population (Supplementary Fig. 12c). The
corresponding time-binned FRET histogram shows a signiﬁcant
decrease in the high-FRET population and a broadening of the
mid-FRET distribution (Fig. 4c, grey), indicating that high DNA
load in crHyb hinders the formation of the active high-FRET
conformation. These results are in agreement with the perturbed
binding kinetics observed (Fig. 3). Taken together, the data with
dCas9:tracrRNA:crHyb conﬁrm the reduced binding afﬁnity for
target DNA and suggest that, in concordance with the detected
in vitro cleavage activity, it can reach the active conformation
required for cleavage but that this state has reduced stability, in
agreement with the reduced cleavage activity in cells (Fig. 5).
To test whether the crHyb-binding defect arises from DNA in
the guide region or the cr repeat region, we measured the binding
dynamics of the Cas9:tracrRNA:crD.Hyb complex, (Fig. 3a).
Interestingly, the data show a partial (3-fold) recovery of the
number of binding observations compared to crHyb, but still
(2.6-fold) less binding than crRNA, also in agreement with the
BLI and SwitchSENSE measurements (Fig. 3b, c and Supplemen-
tary Table 1). However, only 18.5% of trajectories maintained the
stable high-FRET state, while 53% display the dynamic broad
mid-FRET state and the remaining 27% reach the 0.2 FRET state.
The resulting time-binned FRET histogram (Fig. 4c, magenta, n
= 197) shows only a minimal recovery of the high-FRET peak
(compared to crHyb and crRNA), and a minor new peak at ~ 0.2
FRET. These data indicate that while crD.Hyb allows the Cas9
complex to efﬁciently bind target DNA, the active high FRET
conformation remains unstable, which could explain its low
activity in cells (Supplementary Table 1).
We similarly tested crR.Hyb (Fig. 3a). The dCas9:tracrRNA:
crR.Hyb complex displays binding comparable to the full RNA
guide (crRNA) complex, in agreement with the BLI and
SwitchSENSE measurements (Fig. 3b, c and Supplementary
Table 1). The fraction of trajectories reaching the stable high-
FRET is 54% (n= 93/172) and a time-binned histogram shows an
almost identical distribution to that of crRNA (Fig. 4c, green),
both of which indicate that the crR.Hyb dCas9 complex adopts
the stable high-FRET conformation with similar efﬁciency as the
crRNA complex, in agreement with the observed cleavage activity
in cells (Supplementary Table 1).
Overall, the single-molecule results suggest that DNA in the cr
repeat region has little effect on the ability of the complex to
transition from the ‘open’ to stably bound active state. In contrast,
the presence of DNA in the guide region results ﬁrst in an overall
reduced binding afﬁnity and second, when binding occurs, in a
reduced stability of the high-FRET state in favour of the dynamic
mid-FRET state. This suggests that the presence of high DNA
load in the guide region destabilises this state resulting in rapid
transitions between the two.
Tight target engagement is required for cellular activity.
The reduced binding afﬁnity and activity led to the question
of how efﬁciently crHybs would work within the complex
environment of mammalian cells. A mammalian cell reporter
assay was established, using de novo mutations at the human
AAVS1 locus as a readout of Cas9 nuclease activity. The AAVS1
locus is frequently used for genome modiﬁcation and integration
events; alterations at this site are not thought to affect cell
viability23. Repair of the double-strand break caused by Cas9
leads to error-prone non-homologous end joining repair and
base insertion or deletion (InDel) events. These events can
be detected by PCR and Sanger sequencing of the target site
followed by TIDE analysis to deconvolute the sequence traces and
determine mutation frequency24. To introduce these modiﬁed
crXNAs into HEK293 cells, electroporation of pre-formed Cas9:
tracrRNA:crXNA complexes was undertaken. Five days
after transfection, InDel generation at the AAVS1 target site
was measured (Fig. 5).
Cells transfected with Cas9:tracrRNA:crRNA resulted in
populations where over 60% of the AAVS1 loci contained InDels,
indicating efﬁcient targeting of Cas9 nuclease activity to this site.
However, the equivalent Cas9:tracrRNA:crDNA complex caused
no InDel formation, in agreement with our previous in vitro
analysis. Cells transfected with Cas9:tracrRNA:crHybs also
generated no InDels at the AAVS1 site, suggesting that the weak
target-binding afﬁnity is incompatible with targeting nuclease
activity in a complex cellular environment.
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To address this, cells were exposed to Cas9:tracrRNA:crR.Hyb
and Cas9:tracrRNA:crD.Hyb. The cellular InDel efﬁciencies
followed the same pattern as the binding kinetics data, with
crD.Hyb showing no nuclease activity and crR.Hyb generating
mutations as expected. However, InDel generation by crR.Hyb
was fourfold less efﬁcient than crRNA, with an average InDel
frequency of 15.6%. In summary, in vitro functional hybrid
crXNA molecules containing the minimal number of RNA
residues are incompatible with cellular activity, whilst those with
increased RNA content show activity, which is reduced compared
to a fully RNA coded equivalent. This suggests that while tight
target binding is essential for cellular nuclease activity, additional
molecular characteristics are required for full efﬁciency.
tracrHyb can support nuclease activity in vitro. While the
crRNA molecule is required for sequence-speciﬁc targeting of
Cas9, the tracrRNA is the larger cofactor at twice the length of the
crRNA molecule. The tracrRNA makes multiple hydroxyl con-
tacts with Cas9 protein and duplexes with crRNA but is not
thought to directly engage with target DNA2. Having demon-
strated that crHybs were functional in vitro, we questioned
whether the same would be true for the tracrRNA molecule, again
with the potential for reduced synthesis costs and new properties.
Following the same methodology as used to generate crHyb, a
fully DNA tracr (tracrDNA) and a tracrHyb, which contained 10
RNA and 77 DNA residues were generated (collectively referred
to as tracrXNA hereafter; Supplementary Fig. 13a). Using the
same DNA fragmentation in vitro assay described previously, we
found that neither of these molecules could support Cas9
nuclease activity when complexed with any crXNA molecule
(Supplementary Fig. 13b).
To further dissect the backbone requirements for the tracrRNA
and determine if any DNA residues could be tolerated, regions of
the tracrHyb were reverted to RNA and tested for restoration of
activity. To increase the experimental throughput, we ﬁrst split
the tracrRNA into two pieces; previous work has shown that
truncations of the molecule which removed all residues from stem
loop 1 onwards, were still compatible with in vitro nuclease
activity10. The ﬁrst fragment generated (tracr5′) contained the
anti-repeat, stem loop 1 and stem loop 2 whilst the second
(tracr3′) covered stem loops 2 and 3 (Table 1). The length of the
stem loop 2 duplex region was additionally increased to enhance
stability of the duplexed split tracr (Fig. 6a). When complexed
with Cas9 and crRNA or crHyb, the duplexed split-tracrRNA
could direct equivalent cleavage activity to that of the single
tracrRNA molecule (Fig. 6b). Interestingly, when only tracr5′ was
used, full nuclease activity was detected in conjunction with
crRNA but activity was reduced to over 10-fold for crHyb.
Neither crRNA nor crHyb complexed with a hybrid version of
tracr5′ generated cleavage products. Thus, while a crRNA can
function with a minimal tracrRNA, the crHyb requires a full
tracrRNA equivalent for activity.
Each tracrRNA fragment was replaced with a hybrid version to
determine which could tolerate DNA nucleosides. No activity was
detected when tracr5′ contained DNA nucleosides at non-
hydroxyl interacting residues, whereas the combination of a
hybrid tracr3′ and RNA coded tracr5′ gave full activity with both
crRNA and crHyb (Fig. 6b). Therefore, a tracrXNA molecule
partially encoded by DNA on the tracr3′ fragment can direct
speciﬁc Cas9 nuclease activity in vitro.
Attention was then focused on the tracr5′ fragment and within
the hybrid fragment framework we coded areas of stem loop 1, 2
and anti-repeat regions as RNA or DNA (tracr5′ Hyb v2-10;
Fig. 6d and Table 1). Overall, we found that both the anti-repeat
and stem loop 2 regions could tolerate DNA nucleosides (tracr5′
Hyb v4). Stem loop 1 was more sensitive to residue alteration
(tracr5′ Hyb v5-10): we sequentially changed 2–4 bp of RNA to
DNA across this region and could only identify two residues
which could tolerate coding as DNA (tracr5′ Hyb v8). Interest-
ingly, many of the tracrXNA molecules showed enhanced
disruption of activity with crHyb compared to using crRNA
(such as with tracr5′ Hyb v5, v7 and v9). Thus, stem loop 1
appears particularly sensitive to changes in tracrXNA structure,
enhanced by DNA residues in the crXNA.
We inspected the Cas9:sgRNA crystal structure for potential
steric clashes between the introduced thymine residues and the
protein. All additional methyl groups were found over 5 Å from
the protein, except the equivalent of nucleotide 90 where the
group showed a clear clash (Supplementary Fig. 14a). However, it
is possible that rotation of the backbone phosphate could induce a
conformational change to relieve this clash, which correlates with
Table 1 Split tracr fragments sequences
Split tracr
fragment
Sequence. RNA in lowercase and DNA in uppercase DNA/
RNA
Design principal
tracr5′ RNA caaaacagcauagcaaguuaaaauaaggcuaguccguuaucaacuugccuaguggcc
tracr5′ hyb v1 CAAAACAGCATAGCAAguuAaAATAAGGCTAgTCCguuaTCaA
CTTGCCTAGTGGCC
47/10 Structure-guided design
tracr5′ hyb v2 caaaacagcauagcAAguuAaAATAAGGCTAgTCCguuaTCaACTTG
CCTAGTGGCC
33/24 5′-anti-repeat as RNA
tracr5′ hyb v3 CAAAACAGCATAGCaaguuaaaauaaggcuaguccguuaucaacuugccuaguggcc 14/43 Stem loop 1 & 2 as RNA
tracr5′ hyb v4 CAAAACAGCATAGCaaguuaaaauaaggcuaguccguuaucaaCTTGCCTAGTGGCC 28/29 Stem loop 1 as RNA
tracr5′ hyb v5 CAAAACAGCATAGCaaguuaaaATAAGGCTaguccguuaucaacuugccuaguggcc 22/35 ½ stem loop 1 and all stem loop 2 as
RNA
tracr5′ hyb v6 CAAAACAGCATAGCAAguuaaaauaaggcuaguccguuaucaaCTTGCCTAGTGGCC 30/27 Scanning modiﬁcation of v4
tracr5′ hyb v7 CAAAACAGCATAGCaaguuaaaaTAAGGCuaguccguuaucaaCTTGCCTAGTGGCC 34/23
tracr5′ hyb v8 CAAAACAGCATAGCaaguuaaaauaaggcTAguccguuaucaaCTTGCCTAGTGGCC 30/27
tracr5′ hyb v9 CAAAACAGCATAGCaaguuaaaauaaggcuagTCCguuaucaaCTTGCCTAGTGGCC 31/26
tracr5′ hyb v10 CAAAACAGCATAGCaaguuaaaauaaggcuaguccguuaTCaaCTTGCCTAGTGGCC 30/27
tracr3′ RNA ggccactaggcaagtggcaccgagtcggtgcuuuuu
tracr3′ hyb GGCCACTAGGCAAgTgGCACCgAGTCGGTGcTTTTT 36/4
tracr3′ DNA GGCCACTAGGCAAGTGGCACCGAGTCGGTGCTTTTT 40/0
tracrHyb.2 GTTGGAACCATTCAAAACAGCATAGCaaguuaaaauaa
ggcuaguccguuaucaaCTTGAAAAAgTgGCACCgAGTCGGTGcTTTTT
54/33
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the observed cleavage efﬁciencies. In fact, this region could be
coded completely as DNA, with little effect on cleavage
efﬁciencies (Supplementary Fig. 14b, c), again, suggesting
potential clashes in this region are tolerated.
In summary, we have successfully generated hybrid split tracr
molecules, with the most efﬁcient hybrid split tracrXNA
molecules in biochemical assays coded by 50–70% DNA. Taking
these design principals, the standard tracrRNA sequence was
modiﬁed to incorporate DNA nucleosides identiﬁed as compa-
tible from tracr5′ Hyb v4 and tracr3′ fragments. This generated a
new tracrXNA hybrid (tracrHyb.2; Fig. 6c), which was 62% coded
as DNA. In the DNA cleavage assay, a 1.4-fold reduction in
activity was observed with crHyb when compared to the split
tracrXNA equivalent; the now DNA encoded stem loop 2 is likely
more constrained, which may destabilise the complex. However,
when tested with crRNA, cleavage activity equivalent to a
standard tracrRNA molecule was detected (Fig. 6b, signiﬁcance
tests shown in Supplementary Fig. 15). Thus, the tracrXNA can
be modiﬁed to be a majority DNA encoded molecule and retain
in vitro activity.
Biophysical characterisation of tracrHyb.2 using SPR revealed
that binding to Cas9 is comparable to tracrRNA (Supplementary
Fig. 16a and Supplementary Table 2). The SwitchSENSE assay
revealed that target recognition of the Cas9:tracrHyb.2:crXNA
complex had been signiﬁcantly perturbed. The association
kinetics, even using native crRNA, were signiﬁcantly slower
compared with tracrRNA (Figs. 6d and 3c). However, stable
binding was observed for all complexes with slow or negligible
dissociation as seen for tracrRNA (Supplementary Fig. 16b).
These binding characteristics explain the differences seen in the
cleavage assays, with the perturbed binding of Cas9:tracrHyb.v2:
crHyb showing reduced in vitro cleavage efﬁciency.
tracrHyb.2 is functional in eukaryotic cells. Having generated a
functional tracrHyb.2 molecule, activity was tested in the cellular
assay. Following the electroporation assay as previously, we found
that crRNA complexed with Cas9:tracrHyb.2 drove efﬁcient
InDel formation, although a third that of a fully RNA complex
(17% for Cas9:crRNA:tracrHyb.2 compared to 59% for Cas9:
crRNA:tracrRNA; Figs. 5 and 6e). Cas9:tracrHyb.2:crR.Hyb was
also able to generate InDels at low frequencies, whereas Cas9:
tracrHyb.2 complexed with crDNA, crHyb or crD.Hyb was
unable to efﬁciently generate InDels at the AAVS1 locus (Fig. 6e).
Discussion
Cas9 is traditionally guided to its target by associated RNA
molecules, which are inherently less chemically stable than DNA.
Here we have described the design and optimisation of chemically
synthesised hybrid DNA–RNA CRISPR and tracr molecules,
which retain sequence-speciﬁc Cas9 endonuclease activity.
Through rational design we have demonstrated that Cas9 can
tolerate an almost complete change in nucleotide chemistry for
the crXNA molecule, requiring just ﬁve RNA nucleosides
for in vitro activity. These molecules can be used with Cas9 for
in vitro site-speciﬁc nuclease purposes, provide a novel platform
for cellular manipulation and allow development of more stable
and cost-effective reagents for Cas9 applications. There have been
novel in vitro uses of programmable endonucleases as restriction
enzymes25–27 and the DNA–RNA hybrid molecules described
could certainly be adopted into such methods to take advantage
of the improved stability and reduced synthesis costs. Further,
crXNA and tracrXNA provide novel tools for interrogating Cas9
activity and structural requirements through careful manipulation
of binding afﬁnities and associated chemical moieties.
Cas9 tolerated the split tracr designs, with little impact on
overall activity and provided a novel method to quickly assess
designs for the ﬁnal hybridised tracr molecule. We were
successful in converting these split designs into a single tracr
molecule that showed activities comparable to, or even higher
than, the split versions; the increased activities could be due to
improved folding of the single molecule. Interestingly, when
complexing tracrHyb.2 with crHyb, activities were similar or
lower than the split tracr counterparts. Such a decrease could be
due to the additional constraints the deoxyribose backbone place
on the conformation of stem loop 3. It would be interesting to
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further probe this design by lengthening the loop to improve
ﬂexibility of the more rigid DNA molecule.
Through our combination of assays a clear correlation between
target-binding afﬁnity and cellular activity was found (results
from all assays collated in Supplementary Table 1). However,
while the rank order of activities of various Cas9-XNA combi-
nations is maintained across the assays, the absolute activity of
Cas9 was highly dependent on assay type and conﬁguration.
Biochemical in vitro cleavage assays and SwitchSENSE binding
analysis were in good concordance, however both assays tended
to overestimate the cellular activity of Cas9, which was best
correlated with the association kinetics determined in the BLI
assay and the number of binding events observed in the smFRET
assay. There is a fundamental difference in DNA density used in
those assays; both biochemical and SwitchSENSE methods use
relatively low concentrations of target DNA and excess Cas9
complexes. Conversely, in both BLI and cellular assays, local
DNA content greatly exceeds the number of Cas9 complexes,
albeit predominantly on-target in the former and off-target in the
latter. Due to this high DNA concentration, the BLI, but not the
SwitchSENSE, assay required heparin to reduce non-speciﬁc
interactions between Cas9 complexes and non-target DNA. We
hypothesise that high DNA content can amplify the effect of non-
speciﬁc unproductive binding of Cas9 outside its target sites. Such
transient non-speciﬁc binding will compete and interfere with the
search for regions of complementarity. In agreement with this
notion, a recent computational study has suggested that the Cas9
complex undergoes many rounds of target binding and dis-
sociation before nuclease competent binding occurs28. Thus,
inherently frequent and incompetent binding events coupled with
overall reduced afﬁnities of crHyb molecules are therefore
incompatible with efﬁcient searching and target recognition of the
~6400Mb human genome.
There are several possibilities for reduced target association
rates of Cas9 loaded with crHyb molecules. First, the direct
duplexing energies of DNA–RNA are higher than the
DNA–DNA equivalents13,14. Inclusion of DNA in the guide
region will affect the binding energies and thermodynamic sta-
bility of the ﬁnal complex, which is fully supported by the bio-
physical data presented here. Second, Cas9 has evolved to
function with a predominantly A-form DNA–RNA duplex within
the catalytic pocket. While DNA–DNA duplexes can form both A
or B form, the latter is preferred. It is possible that within the
catalytic pocket, the target-guide duplex is presented in a sub-
optimal conformation, reducing binding stability. Third, recent
single-molecule studies have demonstrated that mismatches in
the guide sequence can stall Cas9 in an ‘open’ conﬁguration part
way through the target binding induced structural rearrangement,
with the implication that this is due to reducing stability and
binding energy in the duplex5,6,21. Our data support the notion of
multiple steps of structural reconﬁguration required for efﬁcient
target engagement. Whilst our measurement of tracrRNA and
crXNA-binding afﬁnities are not impacted by Cas9 protein
immobilisation (Supplementary Fig. 16), we did ﬁnd crosslinked
Cas9 showed no interaction with target DNA, likely due to
conformational constraints. The single-molecule FRET data
highlight that weakened binding afﬁnities and stabilities lead to a
dynamic interaction with target DNA, likely though an inability
to stably engage in the fully duplexed conformation. One avenue
for improving activity with crXNA molecules would be through
the use of alternative backbone chemistries that may be more
tolerated by Cas9, or through evolution of Cas9 to accommodate
these molecules more efﬁciently by improving the conformational
changes of the complexes. Joung and colleagues have established a
bacterial assay,20 which could be adapted by electroporating
synthetically generated crXNAs into bacterial cells inducibly
expressing Cas9 variants libraries. This would allow rapid iden-
tiﬁcation of Cas9 mutants that function more effectively with
crXNA in vivo.
Additional factors may also account for the reduced cellular
activity of tracrHyb and crHyb. In vitro, a crHyb molecule should
demonstrate improved stability over a RNA counterpart. How-
ever, the converse could be true in a cellular environment where
the RNaseH family are ubiquitously expressed and will degrade
any DNA:RNA duplex or DNA–RNA hybrid strand29. Thus, one
open question is how protected these molecules are when com-
plexed with Cas9 protein. Protection of crRNA ends by phos-
phate backbone modiﬁcations have been shown to improve
editing efﬁciencies, suggesting that degradation by cellular
enzymes can reduce the half-life of the complex within the cell.
Such modiﬁcation could be employed with crHybs as a potential
area for further improving editing efﬁciencies.
We present here the ﬁrst, to our knowledge, demonstration of
Cas9 activity directed by a predominately RNA-free guide
molecule. Further improvements to this system will be enhanced
by full structural and conformational characterisation of Cas9:
tracrXNA:crXNA complexes. Such characterisations will aid and
direct novel variations within tracrXNA, crXNA or Cas9 protein
to further tolerate altered backbone chemistries and improve
binding properties and catalysis rates. We envisage these insights
will open new avenues for further reductions in Cas9’s ribose
dependency and the generation of fully RNA-free endonucleases
with novel properties, such as enhanced speciﬁcity and stability,
which could be desirable when taking programmable guided
nucleases into therapeutic settings.
Methods
Biochemical cleavage assay. DNA templates were generated by PCR ampliﬁca-
tion using Phusion Flash High-Fidelity polymerase (Thermo Fisher) and the fol-
lowing primers eGFP_fw: 5′-GCT AGC CTC GAG AAT TCT GCA G-3′; eGFP_rv
5′-GCG GCC GCT TTA CTT GTA CA-3′; AAVS1_fw 5′-GCT TGC CAA GGA
CTC AAA CC-3′ and AAVS1_rv 5′-GTC TTC TTC CTC CAA CCC GG-3′. The
cleavage reaction of these templates contained 20 nM Cas9 (New England Biolabs),
60 nM tracrXNA (Dharmacon and Eurogentec), 60 nM crXNA molecules (Inte-
grated DNA Technologies (IDT) and Eurogentec), 1× Cas9 reaction buffer (New
England Biolabs) and 3 nM target DNA. The reaction was incubated at 37 °C for
1 h and terminated by 10 min incubation at 80 °C followed by desalting via dialysis
across a cellulose membrane with a pore size of 0.025 μm (Merck-Millipore).
Fragments were subsequently quantiﬁed by automated QIAxcel agarose gel elec-
trophoresis (Qiagen). Cleavage activity was calculated by dividing the normalised
area of the cleavage products by the normalised area of all fragments. Exemplar raw
gels for Figs. 1 and 2b are shown in Supplementary Figs. 7 and 9, respectively.
For qPCR detection of template depletion, Cas9 cleavage assays were conducted
using 5, 2.5, 1.25 or 0.625 nM Cas9 (New England Biolabs), 15 nM tracrXNA
(Dharmacon and Eurogentec), 15 nM crXNA molecules (IDT and Eurogentec),
1× Cas9 reaction buffer (New England Biolabs), 0.75 nM eGFP and AAVS1 target
DNA. Reactions were stopped after 0, 2, 5, 10, 20, 60 or 120min by addition of equal
volume of 100mM EDTA, 0.1 ngml−1 Proteinase K solution, followed by heating to
65 °C for 5 min. Reactions were diluted 20-fold with water, and then used directly for
qPCR using Luna qPCR Probe Master Mix (New England Biolabs) following the
recommended protocol with the following set of primers and probes; GFP_fw; 5′-
AAG TCG TGC TGC TTC ATG TG-3′, GFP_rv; 5′-GAG GAG CTG TTC ACC
GGG-3′, GFP_probe; 5′-6FAM-ATG AAC TTC AGG GTC AGC TTG C-3′,
AAVS1_fw; 5′-CCT GGT GAA CAC CTA GGA CG-3′, AAVS1_rv; 5′-ACC CTC
TCC CAG AAC CTG AG-3′, AAVS1_probe; 5′-HEX-CTCCGTGCGT
CAGTTTTACC-3′. The reactions were run on an ABI Prism 7900HT cycler and Cts
determined. All samples were measured in triplicate. The derived concentration of the
AAVS1 template was normalised to the input control GFP template using ΔΔCt
method. Time courses were normalised to the starting concentration from the zero
time point. qPCR assay efﬁciency is shown in Supplementary Fig. 8.
All crXNA sequences are given in the ﬁgures except GFP_crRNAm5; 5′-rArGrC
rArArU rGrCrA rCrGrC rCrGrU rArGrG rUrCrG rUrUrU rUrArG rArGrC
rUrArU rGrCrU rGrUrU rUrUrG-3′, GFP_crHybm5; 5′-rAGC AAT GCA CGC
CGrU rAGG rUCG rUrUrU TAG AGC TAT GCT GTT TTG-3′,
AAVS1_crRNAm5; 5′-rGrCrC rArArU rArGrC rCrArG rCrCrC rCrGrU rCrCrG
rUrUrU rUrArG rArGrC rUrArU rGrCrU rGrUrU rUrUrG-3’ and
AAVS1_crHybm5; 5′-rGCC AAT AGC CAG CCrC rCGT rCCG rUrUrU TAG
AGC TAT GCT GTT TTG-3′.
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Cas9 protein production. A synthetic gene coding for Cas9 or catalytically dead
Cas9 (dCas9; D10A and H840A), with an N-terminal 6×HN tag (consisting of 6
histidine and asparagine pairs) and a C-terminal nucleoplasmin nuclear localisa-
tion sequence was synthesised and subcloned into pET24a via NdeI and XhoI
restriction sites to generate pET24a-Cas9. Escherichia coli λBL21DE3* transfor-
mants of pET24a-Cas9 were selected on LB plates containing 100 µg ml−1 kana-
mycin. Large-scale cultures were performed by inoculating 750 ml of TB media at
37 °C, with the cultures grown at 37 °C until OD600= ~ 0.6. The culture tem-
perature was then lowered to 20 °C and protein production induced by the addition
of 100 µM isopropyl β-D-1-thiogalactopyranoside. Incubation was continued
overnight. Cas9 was puriﬁed from cell lysate via immobilised metal afﬁnity chro-
matography. Brieﬂy, cells were lysed using an Avestin Emulsiﬂex C5 in a buffer
consisting of 20 mM Tris Cl (pH 7.5), 300 mM NaCl, 10% glycerol, 1 mM Tris(2-
carboxyethyl)phosphine hydrochloride (TCEP) and 10 mM imidazole, and the
lysate clariﬁed by centrifugation at 20,000 × g for 20 min. The clariﬁed lysate was
loaded onto a 5 ml HisTrap column (GE Healthcare) and, after washing with the
same buffer, eluted with a gradient to 300 mM imidazole. The Cas9-containing
fractions were, after dilution, loaded onto a 5 ml Heparin HiTrap column (GE
Healthcare) and eluted with a linear gradient of 0.1–1M NaCl in a buffer con-
taining 20 mM Tris (pH 7.5), and 10% glycerol. The protein was polished by size-
exclusion chromatography, on a Superdex 26/60 column (GE Healthcare) in a
buffer containing 20 mM HEPES (pH 7.5), 150 mM KCl, 10% glycerol and 1 mM
TCEP. Fractions containing Cas9 were pooled and concentrated to 10–20 mgml−1
and aliquots ﬂash frozen in liquid nitrogen.
AAVS1 cell assay. Synthetic crXNA (IDT or Eurogentec) and tracrXNA molecules
(Dharmacon and Eurogentec) were mixed at equal molarities to give a 960 ng µl−1
solution in duplex buffer (IDT), heated for 5 min at 100 °C and cooled to room
temperature. A volume of 1 µl of the crXNA:tracrXNA mix was added to 1 µg of
Cas9 protein (in-house-puriﬁed) in a total volume of 5 µl of Neon Electroporation
Buffer R (Thermo Fisher). The Cas9:tracrXNA:crXNA complexes were allowed to
form for 10 min at room temperature in low-protein-binding tubes. HEK293 cells
(ATCC) were harvested, washed with phosphate-buffered saline (PBS) and 3.5 ×
105 cells were resuspended in 5 µl of Buffer R supplemented with 0.2 µg of Cas9
Electroporation Enhancer (IDT)30. The cells and Cas9:tracrXNA:crXNA complex
solutions were mixed and electroporated using a 10 µl Neon tip, protocol 24 on the
Neon Transfection System (Thermo Fisher). After electroporation, cells were
seeded into a well of a 24-well plate and incubated for 5 days at 37 °C, 5% CO2.
Cells were then washed in PBS and lysed with DirectPCR buffer supplemented with
0.1 mg ml−1 Proteinase K (Viagen Biotech) following the manufacturer’s instruc-
tions. The AAVS1 target region was ampliﬁed by PCR using Phusion Flash High-
Fidelity polymerase (Thermo Fisher) with the following primers: AAVS1_gen-
ome_fw 5′-GCT TGC CAA GGA CTC AAA CC-3′ and AAVS1_genome_rv 5′-
GTC TTC TTC CTC CAA CCC GG-3′. PCR products were puriﬁed (illustra GFX
PCR DNA and Gel Band Puriﬁcation Kits; GE Healthcare Life Sciences) and
Sanger sequenced. Total InDel efﬁciency was then calculated using TIDE analysis
(https://tide.nki.nl/)24 comparing samples with sequence traces from untransfected
cells.
Biophysical assays. All biophysical assays were performed with in-house-puriﬁed
Cas9 and dCas9 as follows.
Surface plasmon resonance: SPR measurements were carried out at 25 °C using a
Biacore T200 instrument (GE Healthcare Life Sciences). dCas9 was immobilised via
standard amine coupling on a CM5 chip using immobilisation buffer (50 mM
HEPES (pH 7.0), 0.005% Tween-20). The typical immobilisation level observed was
~10,000 RU. Measurement buffer consisted of PBS supplemented with 0.005%
Tween-20. Data were analysed with the BIAevaluation software (GE Healthcare
Life Sciences). Oligonucleotides tested were as above and crHyb.duplex.mut 5′-
rAGC ACT GCA CGC CGrU rAGG rUCT rArArA ATT ACG ATA CGA CAA
AAC-3′.
For experiments with immobilised tracrHyb, the following oligonucleotide was
used 5′-Biotin-TEG-GTT GGA ACC ATT CAA AAC AGC ATA GCrA rArGrU
rUrArA rArArU rArArG rGrCrU rArGrU rCrCrG rUrUrA rUrCrA rACT TGA
AAA ArGT rGGC ACC rGAG TCG GTG rCTT TTT-3′.
Biolayer interferometry: BLI measurements were performed at 25 °C using an
Octet Red96 instrument (ForteBio). The measurement buffer consisted of PBS
supplemented with 0.005% Tween-20, 1 mM MgCl2 and 50 μg ml−1 heparin. SA
tips were used to immobilise ca. 0.1 unit (nm) of 5′-biotinylated duplex DNA oligo
containing a sequence complementary to crXNA molecules (AAVS1-on-target 5′-
biotin-CAC CCT CGT GAC CAC CCT GGA CGG GGC TGG CTA CTG GCT
CAG CCG CTA CC-3′ and non-speciﬁc target 5′-biotin-CAC CCT CGT GAC
CAC CCT GGA CGG GGC TGG CTA CTG GCT CAG CCG CTA CC-3′).
Subsequently, tips were typically dipped in the measurement buffer for 180 s,
transferred to precomplexed dCas9:tracrXNA:crXNA (formed at
100 nM:200 nM:200 nM) for a 30 min association step and ﬁnally moved to the
measurement buffer for a 30 min dissociation step.
SwitchSENSE: SwitchSENSE experiments were performed on a DRX2 analyser
using CST-48-2-G1R1-S chips (both Dynamic Biosensors GmbH, Martinsried,
Germany)31. The chip featured two DNA anchors of different sequence (anchor A,
5′-TAG TGC TGT AGA AGA ATA GAC TCG CTG CTC GTG TTG ACA AGA
ACT GAT-Green 3′ and anchor B, 5′-TCG TCT GTC TCA CTG ATG TAT GAT
TAG TAA GAA CGC TCG CAC GCT GAT-Red 3′), which were optimised for
minimal dCas9 interaction (PAM-free) as well as minimal cross-hybridisation.
Anchors A and B lie in close proximity to each other (average distance 30 nm) on
the chip’s gold electrodes and are labelled at their 3′-end with a green ﬂuorescent
dye and a red ﬂuorescent dye, respectively. dCas9 samples were prepared in
T100K5 buffer (20 mM Trizma Buffer, 100 mM KCl, 5 mM MgCl2 and 0.01%
Tween-20, pH 7.4) and contained precomplexed dCas9:tracrXNA:crXNA (formed
at 20 nM:30 nM:30 nM) and incubated at 37 °C for 20 min.
The kinetic measurements of each dCas9:tracrXNA:crXNA combination
binding to DNA was performed using a standard kinetics assay from the
switchBUILD software from Dynamic Biosensors GmbH. Before each dCas9:
tracrXNA:crXNA injection, anchors A and B were stripped of their complementary
strand with regeneration solution (pH 13, <1 s contact). Subsequently, anchor A
and B were functionalised through hybridisation with a dsDNA overhang
elongated by their respective complementary anchor sequence. The overhang on
anchor A contained a reference sequence (Cas9Ref, 5′-AAA AAA AAA AAA AAA
AAA AAA AAA AAG GAA-complementary anchor A-3′) while the overhang on
anchor B contained the target sequence (Cas9 target, 5′-AAA AAG CCA GTA
GCC AGC CCC GTC CAG GAA-complementary anchor B-3′). Each dCas9:
tracrXNA:crXNA complex was injected at a concentration of 20 nM in T100K5
buffer with a constant ﬂow of 50 µl min−1. The association of dCas9:tracrXNA:
crXNA with each of the strands was observed using the dynamic response of
anchor A and anchor B in real time. Dissociations were performed for 10 min
under a constant ﬂow of 500 µl min−1 T100K5 buffer.
Analysis was performed with the switchANALYSIS software from Dynamic
Biosensors GmbH and Graphpad Prism 6.01. The association rate constants (kon
and koff) and the respective error values were derived from a single exponential ﬁt
model. All oligonucleotides were obtained from Biomers, Germany.
Single-molecule FRET assay: tracrRNA was synthesised by T7 RNAP
transcription, and crXNA guides were synthesised, HPLC-puriﬁed and 5′-Cy5-
labelled by IDT (sequences in Supplementary Table 3). Target DNA with 5′-biotin
and internal amino linker modiﬁed T was synthesised, HPLC-puriﬁed by IDT and
subsequently labelled with Cy3 NHS ester32 and HPLC-puriﬁed in-house. All
oligonucleotides were further puriﬁed by denaturing polyacrylamide gel
electrophoresis, as previously described22.
Flow chambers were prepared as previously described33,34. Brieﬂy, quartz slides
and coverslips were passivated with polyethylene glycol (5% biotinylated) and ﬂow
chambers constructed using double-sided sticky tape and sealed with epoxy. Pre-
annealed dsDNA (ﬁnal concentration 12.5 pM) was immobilised via
biotin–streptavidin interactions. dCas9 complex was formed with 1 µM dCas9, 2
µM tracrRNA and 1 µM labelled crXNA at room temperature for 5 min before
dilution to a ﬁnal concentration of 10 nM with imaging buffer (50 mM Tris-HCl
(pH 8), 100 mM NaCl, 1 mM MgCl2, 0.2 mg ml−1 bovine serum albumin) and
oxygen scavenger system (5 mM 3,4-dihydroxybenzoate (PCA) and 100 nM
protocatechuate-3,4-dioxygenase (PCD)) in saturated Trolox (~ 3 mM). The ﬂow
chambers were imaged on a home-built, prism-based total internal reﬂection
microscope with a 532 nm excitation laser (~ 2 mW), and images acquired on an
EM-CCD camera (Andor) with a 30 ms exposure time. FRET efﬁciencies were
calculated from integrated donor (ID) and acceptor (IA) intensities as FRET= IA/
(ID + IA)33,34.
Images and data were analysed by custom IDL, MATLAB and R scripts,
available upon request. Processed traces used for the transition analysis are given in
Supplementary File 1.
Data availability. All the data generated in this study are available in the manu-
script and accompanying documents or from the authors upon reasonable request.
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